This is the authors' abstract. We don't add key points for this paper.
Purpose: Podocytes are critical components of the glomerular filtration barrier.Their function depends on the integrity of slit diaphragm proteins and dynamic regulation of the actin cytoskeleton.Hyperglycemia-induced cytoskeletal disruption contributes to podocyte injury and the progression of diabetic nephropathy.Umbelliferone, a natural coumarin derivative, was reported to have cytoprotective effects, but its protective role in podocytes under hyperglycemic conditions is unclear.Methods: Conditionally immortalized podocytes were exposed to high glucose levels (33 mM) in the presence or absence of umbelliferone (1-20 μM).The cell viability was assessed using an MTT assay.The expression of slit diaphragm proteins, actin cytoskeletonrelated proteins, Rho GTPase-related proteins, and tight junction proteins was analyzed by western blotting.The cytoskeletal organization and protein localization were evaluated using immunofluorescence and rhodamine-phalloidin staining.Results: High glucose significantly reduced the podocyte viability and decreased the expression of slit diaphragm proteins, including nephrin, podocin, and CD2-associated protein.Hyperglycemic conditions also disrupted actin cytoskeletal organization, as evidenced by the reduced F-actin and α-actinin-4 expression and disorganized actin filaments.The umbelliferone treatment restored the expression and localization of slit diaphragm proteins and improved the cytoskeletal organization.In addition, umbelliferone reversed the hyperglycemia-induced alterations in RhoA, Rac1, and Cdc42 expression and restored the expression and distribution of the tight junction proteins, ZO-1 and occludin.Conclusion: Umbelliferone attenuated hyperglycemia-induced podocyte injury by preserving the slit diaphragm integrity and stabilizing the actin cytoskeletal organization.These protective effects were associated with the modulation of Rho GTPase-related proteins and the restoration of tight junction integrity, suggesting the potential utility of umbelliferone in preventing podocyte dysfunction under diabetic conditions.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: